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Sequence matching analyses show that Clostridium tetani neurotoxin shares numerous pentapeptides (68, including multiple
occurrences) with 42 human proteins that, when altered, have been associated with epilepsy. Such a peptide sharing is higher than
expected, nonstochastic, and involves tetanus toxin-derived epitopes that have been validated as immunopositive in the human
host. Of note, an unexpected high level of peptide matching is found in mitogen-activated protein kinase 10 (MK10), a protein
selectively expressed in hippocampal areas. On the whole, the data indicate a potential for cross-reactivity between the neurotoxin
and specific epilepsy-associated proteins andmay help evaluate the potential risk for epilepsy following immune responses induced
by tetanus infection. Moreover, this study may contribute to clarifying the etiopathogenesis of the different types of epilepsy.
1. Introduction
The term epilepsy defines a group of disturbances whose only
recognized commonality is the paroxysmal synchronous dis-
charging of groups of neurons. Localization and physiological
function of the neuronal populations involved determine
the clinical picture, so that (1) clinical manifestations can
be extremely subtle and the diagnosis can be challenging
also in terms of differential definition; (2) epilepsy(ies) can
produce extremely multiform clinical pictures with a large
degree of overlap [1–3]. Indeed, epileptic syndromes can
also be embedded in larger syndromic clinical pictures,
that is, West and Lennox-Gastaut syndromes in tuberous
sclerosis complex [4, 5].This clinical diversity has noteworthy
nosological implications. Syndromic or disease status of
various forms of epilepsy and the terminology used to define
them are indeed still matter of debate [7–9]. Likewise, the
molecular etiopathogenesis of epilepsies has to be better
defined at the molecular level. Although genetic alterations
[10–12], inflammation [13], and viral infections [14–16]
have been considered and thoroughly studied, nonetheless,
the molecular basis and the causal mechanisms of epilepsies
are still unclear.
Recently, research on epilepsy has also outlined a neu-
rodevelopmental context [17–21]. Spontaneous recurrent
seizures have been observed after induction of status epilepti-
cus during the second and third postnatal weeks in rodents,
by use of chemoconvulsants such as pilocarpine, kainate,
and tetanus toxin (TT) [22]. TT seizures as well as exper-
imental febrile seizures and developmental lithium pilo-
carpine appear to share a commonmechanism for enhancing
hippocampal network excitability and promoting epilepsy,
possibly through alterations in neurotransmitter receptors
or voltage-gated ion channels ([23] and further references
therein).
Moreover, numerous reports suggest that immunemech-
anisms might play a role in processes leading to epileptoge-
nesis [15, 24–32]. In fact, antibodies against neural antigens
involved in neurotransmission have been detected in epilep-
tic subjects [33–39], and, remarkably, epilepsy was shown
to respond to immunotherapeutic approaches [38, 40, 41].
Finally, population-based cohort studies have documented
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that microbial infections during pregnancy may be a risk
factor for epilepsy in offspring [42–45].
In such a multifaceted scientific-clinical context, here we
analyze the peptide commonality between TT, a powerful
neurotoxin used in animal models of experimental epilepsy
[46–50], and human antigens that have been related to
epilepsy, searching for possible immunological link(s) that
might contribute to epileptogenesis. Indeed, a massive pep-
tide overlap characterizes microbial and human proteomes
[51–54] and gives grounds for questioning whether immune
response(s) tomicrobial infectionsmight potentially result in
cross-reactions against neuronal antigens [55–58]. Pathogen
versus human immune cross-reactivity might contribute to
explaining the association between microbial infections and
neurological syndromes [59] and assumes a special signifi-
cance during pregnancy in light of the consequent possible
neurodevelopmental alterations in the fetus and offspring
[26, 58].
We report that the tetanus neurotoxin and human
epilepsy antigens share an ample pentapeptide platform.
The bacterial versus human peptide overlap is not random
and, importantly, a search through the Immune Epitope
Database (IEDB; http://www.immuneepitope.org/) reveals
that the shared pentapeptides are part of TT-derived epitopes.
The latter datum is relevant also in light of the role of
pentapeptides as minimal functional units in cell biology and
immunology [60, 61]. On the whole, the results support the
possibility that immune cross-reactions may occur between
TT and epilepsy-related proteins.
2. Methods
TT protein sequence, UniProtKB/Swiss-Prot accession num-
ber: P04958, 1315aa long, from Clostridium tetani (NCBI
Taxonomic identifier: 212717; further details at http://www
.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi)was ana-
lyzed for pentapeptide sharing with epilepsy-associated pro-
teins as follows. First, a pentapeptide library was constructed
by dissecting the TT primary sequence into pentapeptides
offset by one residue, that is, MPITI, PITIN, ITINN, TINNF,
INNFR, and so forth. Then, each of the final 1311 pentamers
was analyzed for instances of the samematch within a library
consisting of primary sequences of human proteins that,
when altered, have been associatedwith epilepsy.Thenumber
of matches and the human proteins sharing matches were
recorded.
Epilepsy-associated proteins were randomly retrieved
from UniProtKB Database (http://www.uniprot.org/). An
unbiased set of proteins that on whatever basis (i.e., dif-
ferential regulation, protein modification, or mutation) had
been involved in or related to epilepsy was obtained utilizing
“epilepsy” and “Homo sapiens” as keywords. Only canonical
protein sequences were considered. At the time of this study,
the keyword-guided search produced a library of 133 human
UniProt entries, for a total of 106,022aa. Epilepsy-associated
proteins are reported as UniProtKB/Swiss-Prot entry names
throughout the paper, unless when discussed in detail. Any
pentapeptide occurrence in the set of epilepsy-associated
proteins was termed a match.
A set of proteins associated with Down syndrome, a
genetic disease in which infectious agents have no role, was
retrieved from UniProtKB Database and used as a compar-
ison sample. This set was formed by the following proteins
listed according to the aa length, with UniProtKB/Swiss-
Prot entries in parentheses: (1) Down syndrome critical
region protein 10 (P59022, DSC10), 87aa; (2) Down syn-
drome critical region protein 8 (Q96T75, DSCR8), 97aa; (3)
Down syndrome critical region protein 4 (P56555, DSCR4),
118aa; (4) Down syndrome critical region protein 9 (P59020,
DSCR9), 149aa; (5) Down syndrome critical region protein
5 or phosphatidylinositol N-acetylglucosaminyltransferase
subunit P (P57054, PIGP), 158aa; (6) Down syndrome critical
region protein 6 or protein ripply3 (P57055, DSCR6), 190aa;
(7) Down syndrome candidate region 1-like 1 or regulator of
calcineurin 2 (Q14206, RCAN2), 197aa; (8) Down syndrome
candidate region 1-like protein 2 or regulator of calcineurin
3 (Q9UKA8, RCAN3), 241aa; (9) Down syndrome critical
region protein 1 or regulator of calcineurin 1 (P53805,
RCAN1), 252aa; (10) Down syndrome critical region protein
2 or proteasome assembly chaperone 1 (O95456, PSMG1),
288aa; and (11) Down syndrome critical region protein 3
(O14972, DSCR3), 297aa.
The Immune Epitope Database (IEDB; http://www.imm-
uneepitope.org/) was used to search for TT-derived B- and/or
T-cell epitopes that had been experimentally validated as
positive in the human host.
Expected occurrences for pentapeptide sharing between
C. tetani neurotoxin and human proteins associated with
epilepsy were calculated as follows. First, we considered
the number of all possible pentapeptides, N. Since each
residue can be any of 20aa, the number of all possible
pentapeptides N is given by N = 205 = 3.2 × 105. Next, we
considered the TT and epilepsy-associated proteins as two
sets of pentapeptide sizem and n. That is,m is the number of
pentapeptides present in the TT protein and n is the number
of pentapeptides present in the epilepsy-associated protein
set. If X is the number of times a pentapeptide is selected
in the TT protein of size m and Y is the number of times
the same pentapeptide is selected in the epilepsy-associated
protein set, then X =m/N and Y = n/N. Assuming that X and
Y are independent,XY =mn/N2. In otherwords, the expected
number of times that one pentapeptide will be selected
simultaneously in both TT and epilepsy-related protein set is
given bymn/N2. Neglecting the relative abundance of aa and
assuming m ≪ N and n ≪ N, we obtain a formula derived
by approximation where the total number of occurrences
in a second sample n (the epilepsy-related protein set) of
pentapeptides occurring in the first sample m (TT) is given
bymn/N +m/2.
3. Results and Discussion
3.1. Description of the Pentapeptide Sharing between TT and
Epilepsy-Associated Proteins. Peptide sharing between TT
and human epilepsy-associated proteins was analyzed using
(1) the pentapeptide module as a matching probe and (2) a
library consisting of 133 epilepsy-related protein sequences
retrieved from UniProt (see under Methods).
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We used pentapeptides as scanning probes in sequence
similarity analyses since a grouping of five aa residues
may represent a minimal unit of immune recognition in
cellular and humoral responses. Indeed, scientific literature
indicates that an optimal peptide length for T-cell epitopes
ranges between 9 and 15 residues, with the central 5–7 aa
representing the specific immune recognition contacts and
the flanking residues determining the binding potential to the
MHCmolecules [62–66].De facto, the HFMPT pentapeptide
was reported to be aminimal antigenic determinant forMHC
class I-restricted T lymphocytes [65], while the KYVKQ pen-
tapeptide was demonstrated to be a minimal antigenic deter-
minant for CD4(+) T-cell clones [66]; in addition, the IEDB
describes numerous pentapeptide epitopes capable of binding
MHC molecules (e.g., epitope IEDB IDs: 5740, 7948, 11514,
25472, and 33701) and inducing T-cell proliferation (e.g.,
epitope IEDB IDs: 815, 40168, 47974, 59947, 107725, 107725,
and 110376) (reviewed in [61]). Likewise, humoral immune
recognition/reactivity unfolds around short aa motifs ([67–
70]; reviewed in [71]). A representative example is a report by
Zeng and colleagues [70], according to which the C-terminal
pentapeptide (aa sequence: GLRPG) of luteinizing hormone-
releasing hormone is a dominant B-cell epitope able to elicit
a strong anti-LHRH antibody response and to discriminate
between anti-LHRH antibodies present in fertile and nonfer-
tile mice.That is, the pentapeptide GLRPG has immunogenic
and antigenic properties and also discriminates antibody
specificities associated with reproductive competence.
The analyzed set of 133 human proteins related to epilepsy
is listed in Box 1 according to the aa size (i.e., from IR3IP
or immediate early response 3-interacting protein 1, 82aa,
to GPR98 or monogenic audiogenic seizure susceptibility
protein 1 homolog, 6306aa).
Following matching analyses, we found that 42 out of
the 133 epilepsy-associated proteins retrieved at random
from UniProt database share 58 pentapeptides (68 including
multiple occurrences) with the bacterial toxin. Box 2 lists the
epilepsy-related proteins that share pentapeptides with TT
and the shared pentapeptides. No TT pentapeptide match
was found in the comparison set of proteins associated with
Down syndrome.
3.2. Nonstochasticity of the Pentapeptide Sharing between TT
and Epilepsy-Associated Proteins. The comparative analysis
of Boxes 1 and 2 highlights three main points. Firstly, the
68 TT pentapeptide overlap described in Box 2 exceeds the
expected value. As detailed under Methods, the expected
number of TT pentapeptides that may occur in the epilepsy-
related protein set is given by mn/N + m/2, where m is
the number of pentapeptides contained in TT (1,311), n
is the number of pentapeptides contained in the epilepsy-
related protein set (105,490), and N is the number of all
possible pentapeptides (205). Developing the equation gives
43 as expected number of pentapeptide matches, whereas the
observed value is 68 (see Box 2). That is, the pentapeptide
overlap between TT and epilepsy-related proteins is 1.58
times higher when compared to the expected one.
A second point of note is that the distribution of the
pentapeptide overlap through the epilepsy-related proteins
is unexpected. According to equation described above, pen-
tapeptide sharing between two samples is as a quantity
directly proportional to the number of pentapeptides in the
analyzed samples; that is, it is proportional to the protein
aa size. Actually, 91 epilepsy-related proteins are excluded
from the pentapeptide matching with TT, independently
of their length. For example, SPTN1, 2472aa (see Box 1),
has no bacterial matches, while LRRC1, 524aa, shares 3
pentapeptides with TT (Box 2).
In summary, a comparative analysis of Boxes 1 and 2 high-
lights that 68 TT pentapeptide matches are allocated in 42
out 133 human proteins that have been related, when altered,
to epilepsy, and no relationship appears to exist between
pentapeptide sharing and the human protein size. Applying
the equation described above to the set of 42 epilepsy-related
proteins sharing 68 pentapeptides with TT and amounting to
50,254aa, the expected pentapeptide overlap is equal to 20, so
that the observed occurrence value is 3, 4 times higher.
Finally, a third punctum saliens is that nonrandom-
ness characterizes also the distribution of the TT pen-
tapeptides among the 42 epilepsy-associated proteins. Box 2
shows that a few TT pentapeptides are repeated in the
42 epilepsy-associated protein set. Indeed, TT pentapep-
tides EIIPS, SLSIG, and FCKAL recur twice, and TT
pentapeptides FGGQD, KEIEK, and TFLRD occur three
times (Box 2; see pentapeptides underlined). Box 2 also
shows that MK10 (mitogen-activated protein kinase 10;
464aa); CDKL5 (cyclin-dependent kinase-like 5; 1030aa);
and KCMA1 (calcium-activated potassium channel subunit
alpha-1; 1236aa) share two sequentially overlapping pen-
tapeptides with TT, that is, share the hexapeptides SVDDAL,
KNSFSE, and PKEIEK, respectively. The nonrandom TT
pentapeptide sharing clearly emerges from Figure 1, where
expected and observed occurrence values are graphically
compared.
It can be seen that, in conflict with the theoretical trend
of the TT pentapeptide matching as a function of epilepsy-
related protein length (Figure 1, columns in gray), the
observed to expected ratio of pentapeptide matching shows
no relationship with the human protein length (Figure 1,
columns in black). For example, contrary to mathematical
expectations, MK10 (464aa long) has three pentapeptide
matches, whereas VP13A (3174aa long) has one match (see
Box 2 and Figure 1).
3.3. Immunologic Potential of the Pentapeptide Sharing
betweenTTandEpilepsy-Associated Proteins. Having defined
the TT versus epilepsy-associated proteins pentapeptide
overlap, it was next tested whether such a sharing has
an immunologic potential. To this aim we used IEDB, a
database that describes B- and T-cell epitopes for humans,
nonhuman primates, rodents, and other animal species, and
searched for TT-derived epitopes that had been validated as
immunopositive in humans. At the time of the search, we
obtained a list of 517 TT-derived epitopes. The pentapeptides
common to epilepsy-associated proteins and TT (see Box 2,
sequences in italic) were used as probes to scan the 517 TT-
derived epitope set in order to define potential cross-reactive
peptide sequences. Results are reported in Table 1.
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IR3IP (82); CYTB (98); MPC1 (109); OPALI (141); ARF6 (175); DYR (187); CP013 (204); GOSR2 (212);
RB39B (213); SCN1B (218); THEM4 (240); FOLR1 (257); PNPO (261); CLN8 (286); ROGDI (287); KCTD7
(289); SEN34 (310); CLN6 (311); PPR3C (317); PRS41 (318); GHC1 (323); EPM2A (331); PRRT2 (340);
EP2A2 (344); RENR (350); MPRB (354); CLN5 (358); PHF6 (365); LIAS (372); IRK10 (379); CYB (380);
AMACR (382); IRK11 (390); NHLC1 (395); ASAH1 (395); SNIP1 (396); ARC (396); NAGAB (411); BCKD
(412); SIAT9 (418); STRAA (431); CBPA6 (437); DCX (441); PH4H (452); IDHP (452); GBRD (452); GBRA1
(456); NDUV1 (464); MK10 (464); SRPX2 (465); SEN2 (465); GBRG2 (467); MEF2C (473); GBRB3 (473);
SCRB2 (478); AKT1 (480); PUR8 (484); GTR1 (492); KCNA1 (495); KCNV1 (500); ACHB2 (502); ARHG9
(516); JERKY (520); CACB4 (520); D2HDH (521); LRRC1 (524); SEN54 (526); ACHA2 (529); LGI4 (537);
AL7A1 (539); LGI2 (545); LGI3 (548); LGI1 (557); TBC24 (559); ARX (562); TPP1 (563); GGT3 (568); PUR9
(592); STXB1 (594); DCE1 (594); EPMIP (607); LBR (615); ACHA4 (627); EFHC1 (640); SL9A9 (645); ITF2
(667); TSEAR (669); SL9A6 (669); SYN1 (705); EFHC2 (749); TRM44 (757); AFG32 (797); BRAT1 (821);
PRIC1 (831); PRIC2 (844); KCNQ3 (872); KCNQ2 (872); SOBP (873); MANBA (879); CLCN2 (898); PWP2
(919); GABR1 (961); MIB1 (1006); CDKL5 (1030); AT2A2 (1042); DLGP2 (1054); CASR (1078); AP4E1
(1137); PCD19 (1148); TSC1 (1164); ATN1 (1190); ZEB2 (1214); PLCB1 (1216); KCMA1 (1236); DPOG1
(1239); TPC10 (1259); CNTP2 (1331); ARHGA (1369); NMDE1 (1464); WDR62 (1518); ABCC8 (1581);
GCP6 (1819); SCN8A (1980); SCN9A (1988); SCN2A (2005); SCN1A (2009); CAC1E (2313); CAC1H (2353);
SPTN1 (2472); VP13A (3174); RELN (3460); CSMD3 (3707); GPR98 (6306)
Box 1: List of the 133 epilepsy-associated proteins analyzed for TT pentapeptide sharing. Proteins were randomly retrieved from UniProtKB
(http://www.uniprot.org/) as described under Methods. Proteins are indicated by UniProtKB/Swiss-Prot entry names, and listed according
to increasing aa length reported in parentheses.
ROGDI (LKDKI); CLN6 (PALLL); CLN5 (VIVHK); NHLC1 (TITND); ASAH1 (PVLNK); CBPA6 (GIPYA);
GBRA1 (VSFWL); MK10 (SVDDAL∗, GAQGI); GTR1 (SYLSI); ARHG9 (KLEEK); D2HDH (GSGLV);
LRRC1 (NKNEV, SLTDL, FCKAL); ACHA2 (NITSL, EIIPS); LGI2 (KAKWL); LGI1 (GFTEI); EPMIP (SGLVS);
ACHA4 (EIIPS); EFHC1 (RVPKV); SL9A9 (IMYGF); TSEAR (QGYEG); SL9A6 (SIMYG, SPTTL); EFHC2
(GDFIK); AFG32 (DPALL); CLCN2 (TFRDL); PWP2 (GQYIV, HSLSI); GABR1 (EDIDV); CDKL5
(KNSFSE∗, SLSIG); TSC1 (LKKLE); KCMA1 (FCKAL, PKEIEK∗); CNTP2 (DFIKL); ARHGA (KLVKA);
NMDE1 (PALNI); WDR62 (LIHVL, KRSYQ, TNGKL); GCP6 (SLSIG, KEIEK); SCN8A (FGGQD, DTQSK,
LRVPK, TFLRD); SCN9A (NDMFN); SCN2A (FGGQD, TFLRD); SCN1A (FGGQD, TFLRD); VP13A
(ITMTN); RELN (SIGSG); CSMD3 (EGFNI, KEIEK); GPR98 (LISID, ESKDL, VDGSG, TLPND, SGFNS, LSSAN, VQLKN)
Box 2: Peptide sharing between TT and epilepsy-associated proteins. Proteins reported by UniProtKB/Swiss-Prot entry names and listed
according to the aa length. Pentapeptides shared with TT are italic in parentheses. Pentapeptides present more than once in the epilepsy
antigen set are underlined. Sharing of two consecutively overlapped pentapeptides (i.e., a hexapeptide) is indicated by an asterisk.
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Figure 1: Observed versus expected pentapeptidematching between TT and epilepsy-related proteins.The 42 proteins sharing pentapeptides
with TT are allocated along the x-axis according to increasing aa length. Gray columns: expectedmatches calculated according to the formula
mn/N + m/2, where m is the number of pentapeptides present in the neurotoxin (1,311) and n is the number of pentapeptides present in the
epilepsy-associated protein (see Methods). For example, in the case of IR3IP protein, 82aa, the possible pentapeptide overlap is equal to 1,311
× 78/3,200,000 + 1,311/2. Black columns: observed to expected ratio of the pentapeptide matching. Observed matching values from Box 2.
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In essence, Table 1 shows that all of the 58 pentapeptides
common to the 42 epilepsy-associated proteins and TT
(Box 2, peptide sequences in parentheses and in italic) are
present in 116 TT-derived epitopes that had been established
to be immunopositive in humans. This datum indicates a
potential vulnerability of the 42 epilepsy-associated proteins
to cross-reactions following anti-TT immune responses.
Moreover, many TT-derived epitopes share fragments with
distinct epilepsy-related proteins and are of particular signif-
icance to a multiple cross-reactivity risk, since, for example,
an immune response targeting the TT epitope fnnftVS-
FWLRVPKVsahle (see Table 1, IEDB ID 17207, with shared
fragments in capital letter) has the potential to cross-react
with the following three crucial proteins related to different
forms of epilepsy:
(i) GBRA1 or gamma-aminobutyric acid receptor sub-
unit alpha-1, themajor inhibitory neurotransmitter in
the vertebrate brain thatmediates neuronal inhibition
by binding to the GABA/benzodiazepine receptor
and opening an integral chloride channel [72],
(ii) SCN8A or voltage-gated sodium channel subunit
alpha Nav1.6, a protein that mediates the voltage-
dependent sodium ion permeability of excitable
membranes [73],
(iii) EFHC1 or myoclonin-1, a protein that may enhance
calcium influx through CACNA1E and stimulate
programmed cell death [74].
Such a multiple cross-reactivity potential is shown also
by other TT-derived epitopes, eg, epitopes IEDB IDs 30436,
48049, 113407, and so forth.
Also, it seems important to highlight that MK10
(mitogen-activated protein kinase 10, also known as stress-
activated protein kinase JNK3 or p493F12 kinase), a protein
that shows the highest unexpected level of pentapeptide
overlap to TT (Figure 1) and also has a high immunologic
potential as illustrated in Table 1 (i.e., MK10 pentapeptide(s)
are present in 7 TT-derived epitopes), is selectively expressed
in a subpopulation of pyramidal neurons in the CA1, CA4,
and subiculum regions of the hippocampus, and layers 3
and 5 of the neocortex [75]. That is, there is a potential
cross-reactivity risk specifically allocated in brain areas
directly linked to epileptogenesis [76, 77].
4. Conclusions
This study describes a vast pentapeptide commonality
between TT-derived epitopes and epilepsy-associated pro-
teins. This peptide sharing acquires a relevant pathologic
potential in light of the fact that pentapeptide modules have
the capacity of inducing immune response(s) and are main
players in immune recognition [61–71]. Immunologically,
two sequences that share a pentapeptide are potentially
subject to a cross-reaction [60].
In the disease model examined here, that is, tetanus
infection and epilepsy, the ample cross-reactivity platform
between TT-derived epitopes and human epilepsy-associated
antigens supports the hypothesis of an immune involvement
in epilepsy. As a matter of fact, all the 42 epilepsy-related
proteins listed in Box 2 are potential targets of cross-reactions
(see Table 1). Qualitatively, the peptide overlap occurs
in human proteins canonically associated with epilepsy
such as gamma-aminobutyric acid receptor subunit alpha-
1 (GBRA1), gamma-aminobutyric acid type B receptor sub-
unit 1 (GABR1), sodium channel protein subunits (SCN1A,
SCN2A. SCN8A, and SCN9A), and calcium-activated potas-
sium channel subunit alpha-1 (KCMA1) (Table 1). Obviously,
an immune attack against such epilepsy-associated proteins
may cause alterations to neural structures and functions,
especially when the neurodevelopmental intrauterine phase
is considered. Being of nonsecondary importance, the non-
stochastic character of the peptide overlap between TT
and epilepsy-associated proteins (Figure 1) indicates that the
potential cross-reactivity extent (and the associated risk of
developing epilepsy and neurodevelopmental disorders) will
increase with the number of anti-TT immune stimulations.
An additional relevant point is the “antigenic patchwork”
shown in Table 1. Indeed, the potential peptide crossreactome
involved in different extent and in different combinations of
42 epilepsy-associated proteins might help understand the
complex neurobiological network that, once hit and per-
turbed, may underlie different epileptic forms [1–9]. Also, it
has to be noted that Table 1 includes proteins such as CNTP2
or contactin-associated protein-like 2, RELN or reelin, and
TSC1 or tuberous sclerosis 1 protein, which are also landmark
antigens for autism and the associated impairment in com-
munication/language skills and behaviors [78–81]. Hence,
Table 1 may provide a mechanistic framework to allocate
the occurrence of epilepsy, intellectual disability, and autism
spectrum disorder in patients with tuberous sclerosis com-
plex. Likewise, data from Table 1 might contribute to answer-
ing a critical question in neuropsychopathology, that is, the
coexistence of patients with combined schizophrenia and
epilepsy [82–85]. Indeed, Table 1 substantiates the hypoth-
esis according to which the thread joining epilepsy and
schizophrenia may reside in neurodevelopmental molecules
such as leucine-rich glioma inactivated (LGI) proteins and
GPR98, a G protein-coupled receptor, originally known as
VLGR1 or very large G protein-coupled receptor [86]. De
facto, Table 1 shows that fragments from LGI1, LGI2, and
GPR98 are present in 1, 7, and 18 TT-derived epitopes, respec-
tively. In other words, the potential cross-reactivity targeting
LGI1, LGI2, and GPR98 following an anti-TT response is
high.
Given the caveat that peptide immunoreactivity is influ-
enced by numerous factors, for example, binding affinity
[87], cripticity (i.e., determinants embedded in membrane
structures do not induce immune responses under physio-
logical conditions) [88], and posttranslational modifications
(i.e., citrullination) [89], the present data might contribute
to further our understanding of epilepsies. In particular,
data from Table 1 might represent a peptide platform to be
tested in antibody binding assays using sera from epileptic
subjects. Accompanied by parallel immunoassays based on
the utilization of epilepsy-related proteins as antigens, such
an approach might not only validate the TT-epilepsy link
proposed in this study, but also lead to a definition at
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Table 1: Pentapeptide sharing between TT-derived epitopes and human epilepsy-associated proteins.
IEDB ID1 TT-derived epitope2,3 Immune context Epilepsy-associated proteins4
1270 afcpeyvptfdnvieNITSL HLA-Class II, allele undetermined ACHA2
1389 afrnVDGSGLVSklig HLA-Class II, allele undetermined GPR98 D2HDH EPMIP
1501 agevrqiTFRDLpdkfnayl HLA-Class II, allele undetermined CLCN2
1929 aihlvnnesseVIVHKamdi HLA-DRB1∗04:01 CLN5
2219 akkqllefDTQSKnilmqyi HLA-Class II, allele undetermined SCN8A
3156 amltnliifgpgPVLNKNEV HLA-Class II, allele undetermined ASAH1 LRRC1
3418 anskfigiteLKKLEskink HLA-DRB1∗11:01 TSC1
3832 apsyTNGKLniyyrrlyngl HLA-DRB5∗01:01, HLA-DRB1∗13:01 WDR62
7603 danLISIDikndlyektl HLA-DRB1∗03:01 GPR98
8734 dinndiisdiSGFNSsvity HLA-DRB1∗01:01 GPR98
8778 diSGFNSsvitypdaqlvpg HLA-DRB1∗15:01 GPR98
/8903 dkisdvstivpyigPALNIv HLA-DPB1∗04:01, HLA-DRB1∗15:01 NMDE1
9297 dltfiaeKNSFSEepfqdei HLA-DRB1∗01:01, HLA-DRB1∗04:01 CDKL5
9595 DPALLLmheLIHVLhglyg
B-cell
HLA-DR2; HLA-Class II, allele
undetermined
AFG32 CLN6WDR62
9595 drLSSANlyingvlmgsaei
B-cell
HLA-DR2; HLA-Class II, allele
undetermined
GPR98
10472 DTQSKnilqyikanskfigiteLKKLEski HLA-Class II, allele undetermined SCN8A TSC1
11980 efDTQSKnilmqyikanskfigitel B-cell SCN8A
13095 eLIHVLhglygmqvss
B-cell
HLA-DR2; HLA-Class I, allele
undetermined
WDR62
13125 eLKKLEskinkvfstpipfs HLA-Class II, allele undetermined TSC1
13813 eqdpsgattksamltnliifgpgPVLNKNEV HLA-Class II, allele undetermined ASAH1 LRRC1
15087 eysiessmkkHSLSIGSGwsvsl B-cell PWP2 GCP6 CDKL5 RELN
15411 fdkdsnGQYIVnedkfqily HLA-Class II, allele undetermined PWP2
16155 fiaeKNSFSEepfqdeivsyntk B-cell CDKL5
17134 fnaylankwvfiTITNDrls HLA-Class II, allele undetermined NHLC1
17205 fnnftVSFWLRVPK HLA-Class II, allele undetermined GBRA1 SCN8A
17206 fnnftVSFWLRVPKVsahle HLA-DR3 GBRA1 SCN8A EFHC1
17207 fnnftVSFWLRVPKVsashle
HLA-DRB1∗11:01, HLA-DR, HLA-DR1,
HLA-DR5, HLA-DR7, HLA-DR11,
HLA-DPw4, HLA-Class II, allele
undetermined
GBRA1 SCN8A EFHC1
17208 fnnftVSFWLRVPKVsashleqy HLA-DRB1
∗01:01, HLA-DRB1∗04:01,
HLA-HLA-DRB1∗07:01, HLA-DRB1∗11:01 GBRA1 SCN8A EFHC1
17487 fqilynSIMYGFTEIelgkk HLA-Class II, allele undetermined SL9A6 SL9A9 LGI1
18217 fvksGDFIKLyvsynnnehivgy B-cell EFHC2 CNTP2
18356 fwLRVPKVsashleqygtne HLA-DRB1∗11:01 SCN8A EFHC1
19469 gevrqiTFRDLpdkfnaylankw B-cell CLCN2
21599 gpdkeqiadeinnlknKLEEKan B-cell ARHG9
22769 gtneysiissmkkHSLSIGS DQB1∗06:02, DRB5∗01:01 PWP2 GCP6 CDKL5
24238 hLKDKIlgcdwyfvptdegwtnd HLA-Class II, allele undetermined ROGDI
25597 idkisdvstivpyigPALNI HLA-Class II, allele undetermined NMDE1
25666 idsfvksGDFIKLyvsynnn HLA-DRB1∗15:01 EFHC2 CNTP2
26808 ikiknedltfiaeKNSFSEe HLA-Class II, allele undetermined CDKL5
27639 ingkaihlvnnesseVIVHK HLA-Class II, allele undetermined CLN5
Epilepsy Research and Treatment 7
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IEDB ID1 TT-derived epitope2,3 Immune context Epilepsy-associated proteins4
29241 ivdynlqskiTLPNDrttpv HLA-Class II, allele undetermined GPR98
29331 ivkQGYEGnfig HLA-Class II, allele undetermined TSEAR
29407 ivpyigPALNIv HLA-Class II, allele undetermined NMDE1
29408 ivpyigPALNIvkQGYEGnf HLA-DRB1∗15:01 NMDE1 TSEAR
29843 KAKWLgtvntqfqKRSYQ HLA-Class II, allele undetermined LGI2 WDR62
29891 kamdieyNDMFNnftVSFWLrvp B-cell SCN9A GBRA1
30269 kdVQLKNitdymyltnapsy HLA-DRB1∗01:01, HLA-DRB1∗04:01 GPR98
30436 KEIEKlytSYLSITFLRDpwgnp B-cell CSMD3 KCMA1 GCP6 GTR1SCN1A SCN2A SCN8A CLCN2
30572 keqiadeinnlknKLEEKan HLA-Class II, allele undetermined ARHG9
32521 knitdymyltnapsyTNGKL HLA-Class II, allele undetermined WDR62
32546 knldcwvdneEDIDVilkkstil B-cell GABR1
33527 kstilnldinndiisdiSGFNSs B-cell GPR98
34301 kwievyKLVKAKWLgtvntq HLA-DRB1∗01:01 ARHGA LGI2
34887 lankwvfiTITNDrLSSANlyin B-cell NHLC1 GPR98
35058 lcikiknedltfiaeKNSFS HLA-DRB1∗04:01 CDKL5
35566 lekryekwievyKLVKAKWL HLA-Class II, allele undetermined ARHGA LGI2
35993 lftFGGQDanLISIDikndl HLA-Class II, allele undetermined SCN1A SCN2A SCN8A GPR98
36667 lipvassskdVQLKNitdym HLA-DRB1∗11:01 GPR98
38977 lqrITMTNSVDDALinstki HLA-Class II, allele undetermined VP13A MK10
40770 lygmqvsshEIIPSkqeiym HLA-Class II, allele undetermined ACHA2 ACHA4
41527 mfnnftVSFWLRVPKVsash HLA-DRB1∗11:01 GBRA1 SCN8A EFHC1
42847 mtnSVDDALinstkiysyfp HLA-DRB1∗11:01 MK10
43280 napsyTNGKLniyyrrlynglkf B-cell WDR62
43519 ndrLSSANlyingvlmgsae HLA-Class II, allele undetermined GPR98
43591 neEDIDVilkkstilnldin HLA-Class II, allele undetermined GABR1
43939 nftVSFWLRVPK HLA-Class II, allele undetermined GBRA1 SCN8A
43940 nftVSFWLRVPKVsashle HLA-DRB1∗11:01 GBRA1 SCN8A EFHC1
44007 ngkaihlvnnesseVIVHKamdi B-cell CLN5
44396 nivkQGYEGnfi HLA-Class II, allele undetermined TSEAR
44200 niddntiyqylyaqkSPTTL HLA-DRB1∗01:01 SL9A6
44383 NITSLtigkskyfqDPALLL HLA-ClassII, allele undetermined ACHA2 AFG32 CLN6
44557 NKNEVrgivlrvdnknyfpc HLA-Class II, allele undetermined LRRC1
44667 nldinndiisdiSGFNSsvi HLA-Class II, allele undetermined GPR98
45102 nnftVSFWLRVPKVsashle HLA-Class II, allele undetermined GBRA1 SCN8A EFHC1
46136 ntiyqylyaqkSPTTLqrit HLA-Class II, allele undetermined SL9A6
46853 PALLLmheLIHVLhglygmq HLA-Class II, allele undetermined CLN6WDR62
46855 PALNIvkQGYEGnfigalet HLA-Class II, allele undetermined NMDE1 TSEAR
48049 PKEIEKlytSYLSITFLRDf HLA-Class II, allele undetermined GCP6 CSMD3 KCMA1 GTR1SCN1A SCN2A SCN8A CLCN2
48697 pnrdiliasnwyfnhLKDKIlgc B-cell ROGDI
49984 pvtkGIPYApeyksnaastteih B-cell CBPA6
51254 qkSPTTLqrITMTNSVDDALIns B-cell SL9A6 VP13A MK10
56528 ryekwievyKLVKAKWLgtvntq B-cell ARHGA LGI2
57935 sfvksGDFIKLyvsynnneh HLA-ClassII, allele undetermined EFHC2 CNTP2
57947 sfwLRVPKVsashle HLA-DR5, HLA-DRB1∗11:01 SCN8A EFHC1
58527 SIGSGwsvslkgnnliwtlk HLA-DRB1∗03:01 RELN
59500 SLTDLggelcikikn HLA-Class II, allele undetermined LRRC1
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61214 ssmkkHSLSIGSGwsvslkg HLA-Class II, allele undetermined PWP2 GCP6 CDKL5 RELN
61354 ssskdVQLKNitdymyltnapsy B-cell GPR98
62073 SVDDALinstkiysyfpsviskvnqGAQGIl HLA-Class II, allele undetermined MK10
63277 tdymyltnapsyTNGKLniy HLA-DRB1∗01:01, HLA-DRB1∗04:01 WDR62
63450 teLKKLEskinkvfstpipf HLA-DRB1∗07:01 TSC1
64514 tiyndtEGFNIESKDLksey HLA-Class II, allele undetermined CSMD3 GPR98
65324 TNGKLniyyrrlynglkfii HLA-Class II, allele undetermined WDR62
67104 tvntqfqKRSYQmyrsletqvda B-cell WDR62
67147 tVSFWLRVPKVsa HLA-DRB1∗11:01, HLA-DRB1∗11:04 GBRA1 SCN8A EFHC1
67148 tVSFWLRVPKVsashle HLA-DRB1∗11:01 GBRA1 SCN8A EFHC1
68104 vdynlqskiTLPNDrttpvt HLA-DQB1∗06:02 GPR98
69149 VIVHKamdieyNDMFNnftv HLA-Class II, allele undetermined CLN5 SCN9A
69180 vKAKWLgtvntqfqKRSYQm HLA-DQB1∗06:02 LGI2 WDR62
70202 vntqfqKRSYQmyrsleyqv HLA-DRB1∗07:01 WDR62
70165 vnqGAQGIlflqwvrdiidd HLA-Class II, allele undetermined MK10
70166 vnqGAQGIlflqwvrdiiddftn B-cell MK10
70514 vpyigPALNIvk HLA-Class II, allele undetermined NMDE1
70982 vsidkfriFCKALnpk HLA-DRB1∗11:01 LRRC1 SCN8A KCMA1
71155 vstivpyigPALNI HLA-DR, HLA-DR1, HLA-A∗02:01 NMDE1
71156 vstivpyigPALNIvkQGYEGnf B-cell NMDE1 TSEAR
72784 wLRVPKVsashleqygtneysie B-cell SCN8A EFHC1
76411 yvsidkfriFCKALnPKEIE HLA-Class II, allele undetermined LRRC1 KCMA15
76537 yylipvassskdVQLKNitd HLA-Class II, allele undetermined GPR98
79808 eLIHVLhglygmq HLA-DRA∗01:01, HLA-DRB1∗01:01 WDR62 KCMA1
79816 evyKLVKAKWLgt HLA-DRA∗01:01, HLA-DRB1∗01:01 ARHGA LGI2
113407 fnnftVSFWLRVPKVsas HLA-DR11 GBRA1 SCN8A EFHC1
167585 glygmqvsshEIIPSkqeiy HLA-DRB1∗12:01 ACHA2 ACHA4
167613 kvnqGAQGIlflqwvrdiid HLA-DRB1∗12:01 MK10
167626 nLISIDikndlyektlndyk HLA-DRB1∗12:01 GPR98
167666 shEIIPSkqeiymqhtypis HLA-DRB1∗12:01 ACHA2 ACHA4
1One hundred and sixteen linear TT-derived epitopes that had been found to be immunopositive in the human host were analyzed. Epitope number refers to
IEDB ID. Further details and references are reported in the Immune Epitope Database (IEDB; http://www.immuneepitope.org/.
2Aa sequences given in one-letter code.
3Peptide fragments shared with epilepsy-associated proteins in capital.
4Epilepsy-associated proteins reported as UniProt/Swiss-prot entries. For details and references, see http://www.uniprot.org/.
5TT-derived epitope ID 76411 shares both pentapeptides FCKAL and PKEIE with human KCMA1 (or calcium-activated potassium channel subunit alpha-1).
the molecular level of the repeatedly advanced association
between antibodies and epilepsy [33–41]. Moreover, of not
less importance, immunoassay validation could also repre-
sent a prelude to specific therapies based on peptide modules
able to block epileptogenic anti-TT autoantibodies [38–
41, 90]. Immunological research in this direction has been
programmed in our lab.
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